Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr 1;1(2):77-9.
doi: 10.4161/jkst.20293.

The interplay between inhibition of JAK2 and HSP90

Jordan S Fridman  1 , Nicholas J Sarlis
Affiliations

The interplay between inhibition of JAK2 and HSP90

Jordan S Fridman et al. JAKSTAT. .

Abstract

A recent article by Weigert et al. published in The Journal of Experimental Medicine described the in vitro generation of synthetic mutations in Janus kinase 2 (JAK 2) that decreased the potency of JAK2 (or JAK1/JAK2) inhibitors in artificial systems. The authors found that heat shock protein 90 (HSP90) inhibitors circumvented the potency shift and suggested that HSP90 inhibition may abrogate JAK inhibitor resistance in these experimental systems. However, the clinical relevance of these laboratory-generated JAK2 mutations, which have not been identified to-date in patients treated with JAK inhibitors, and the therapeutic potential of HSP90 inhibitors in diseases involving aberrant JAK-STAT signaling remain to be determined.

Keywords: HSP90; JAK inhibitor; Janus kinase; mutation; resistance.

PubMed Disclaimer

Figures

None
Figure 1. A model based on the findings of the study by Weigert et al. would imply that in the presence of certain JAK2 mutations, JAK2 inhibitors may be unable to maximally inhibit JAK-STAT signaling (A). In this model, the co-administration of an HSP90 inhibitor could supplement the effect of a JAK2 inhibitor to overcome compromised JAK2 inhibitor potency (B).
See this image and copyright information in PMC

Comment on

  • Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012;209:259–73. doi: 10.1084/jem.20111694. doi: 10.1084/jem.20111694

References

    1. Press release. FDA approves Incyte’s Jakafi™ (ruxolitinib) for patients with myelofibrosis. 11/16/11.
    1. JAKAFI™ (ruxolitinib) prescribing information. Incyte Corporation, Wilmington, DE. 2011.
    1. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/results?term=ruxolitinib. Accessed 3/2/12.
    1. Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012;209:259–73. doi: 10.1084/jem.20111694. - DOI - PMC - PubMed
    1. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer. 2010;1:979–93. doi: 10.1177/1947601910397187. - DOI - PMC - PubMed